Skip to content
OpenCapital
Get started

Incyte INCY TABRECTA — Total revenues

Other product segments

JAKAFI
$816.66M+6.9%
OPZELURA
$449.74M+173%
JAKAVI Royalty Revenues
$124.19M+13.2%
NIKTIMVO
$60.31M+66.8%
MINJUVI/MONJUVI
$53.69M+72.5%
ZYNYZ
$49.95M+460%
OLUMIANT Royalty Revenues
$38.48M+14.9%
ICLUSIG
$34.39M+5.1%
PEMAZYRE
$23.42M+5.5%
Milestone and contract revenues
$11.2M+124%
TABRECTA Royalty Revenues
$6.69M+0.9%
Other product royalty revenues
$5.33M+314%

Similar metrics at other companies

Gilead Sciences logo
GILDTecartus — Total revenues
$75M-3.8%
ALN
ALNYTotal TTR — Total revenues
$1.03B+89.2%
Jazz Pharmaceuticals logo
JAZZTotal Revenue
$1.07B+19.1%
BioMarin Pharmaceuticals logo
BMRNTotal Revenue
$766.21M+2.8%
Axsome Therapeutics logo
AXSMTotal Revenue
$191.2M+57.4%
Revvity logo
RVTYTotal Revenue
$711.12M+7.0%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$25.96B+70.1%
Enterprise value$22.01B+64.9%
P/E16.1×-1.4×
P/S4.5×+1.1×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0×0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's tabrecta — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's TABRECTA — total revenues?
Incyte (INCY) reported TABRECTA — total revenues of $6.7M in Q2 2026.
How has Incyte's TABRECTA — total revenues changed year-over-year?
Incyte's TABRECTA — total revenues increased by 1.5% year-over-year, from $6.6M to $6.7M.
What is the long-term trend for Incyte's TABRECTA — total revenues?
Over 3 years (2021 to 2025), Incyte's TABRECTA — total revenues has grown at a 37.2% compound annual growth rate (CAGR), from $10.3M to $26.6M.
What does TABRECTA — total revenues mean?
This metric represents the total gross revenue generated from the sale and commercialization of a specific oncology therapeutic product. It reflects the market adoption, pricing power, and patient demand for the drug within its indicated patient population. This figure is a primary indicator of the product's contribution to the company's overall top-line performance.